Highlights Newsletter 3

This newsletter presents you the following key sessions:

• Watch the video interview with prof. Daniel P. Petrylak about update of the phase III RANGE study

• Longer survival with second line pembrolizumab in patients with advanced urothelial cancer

• Superior progression-free survival with osimertinib over erlotinib, or gefitinib in the upfront treatment of EGFR mutated NSCLC

• No benefit of neoadjuvant chemotherapy followed by surgery in locally advanced cervix cancer: chemoradiation should remain the standard of care

• Dabrafenib and trametinib doubles the relapse-free survival in patients with stage III BRAF mutant melanoma